Potential, Phase 2, novel therapies in SLE: OBIN (anti-CD20 mAb), BIIB059 (BDCA2 binder), & IBD (modulator of the E3 ubiquitin ligase complex) showed efficacy. EVO (oral BTKi) failed to show efficacy. Drs. Fleischmann and @alvinwellsmd #RWCS2021 #RWCS @RheumNow @RWCSmtg https://t.co/i04nx71GSx